Clinical Trials on Invasive Bladder Urothelial Carcinoma

Total 1378 results

National Cancer Institute (NCI)

Recruiting

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Platinum-Resistant Urothelial Carcinoma

United States
University of Virginia
American Cancer Society, Inc.; Integrated Translational Health Research Institute...

Recruiting

Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) (PRIMER)

Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Stage II Bladder Cancer AJCC v8 | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Hydronephrosis | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Renal Pelvis Cancer AJCC v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Renal Pelvis Cancer AJCC v7 | Stage IV... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Locally Advanced Urothelial Carcinoma

United States, Canada
University of Utah
Exelixis

Active, not recruiting

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

Bladder Cancer | Metastatic Urothelial Carcinoma

United States
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
David D'Andrea

Not yet recruiting

Single-Dose Intravesical Chemotherapy After Diagnostic URS (MINERVA)

Bladder Cancer | Upper Urinary Tract Urothelial Carcinoma

Austria
University of Florida

Not yet recruiting

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Urothelial Carcinoma Bladder
RenJi Hospital
Peking University First Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Circulating Tumour DNA and Urine Tumor DNA Detection of Minimal Residual Disease in Locally Advanced Upper Tract Urothelial Carcinoma With Radical Nephroureterectomy: A Cohort Study

Muscle Invasive Upper Tract Urothelial Carcinoma

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Prostate Cancer | Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Active, not recruiting

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer (GEMDOCE)

Bladder Cancer | Urothelial Carcinoma Bladder

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Bladder Urothelial Cancer

China
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR)

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Ureter Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Localized Renal Pelvis and Ureter Urothelial Carcinoma | Stage II Bladder... and other conditions

United States, Guam
The Methodist Hospital Research Institute
Pfizer

Recruiting

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)

Urothelial Carcinoma Bladder

United States
Bernie Eigl
Lady Davis Institute; Vancouver Prostate Centre; Bladder Cancer Canada

Recruiting

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Metastatic Urothelial Carcinoma | Metastatic Bladder Cancer

Canada
Varian, a Siemens Healthineers Company
Rigshospitalet, Denmark; Herlev Hospital

Recruiting

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach (ARTIA-Vesica)

Muscle-Invasive Bladder Carcinoma

Denmark
Elypta
Lund University

Recruiting

AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study (AUR93A)

Muscle-Invasive Bladder Carcinoma

Sweden, Denmark, Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital...

Not yet recruiting

Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.

Muscle-Invasive Bladder Carcinoma
IRCCS San Raffaele
Bristol-Myers Squibb

Recruiting

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo)

Muscle-Invasive Bladder Carcinoma

Italy
C2i Genomics
Fox Chase Cancer Center; Baylor College of Medicine; New York University; The Cleveland... and other collaborators

Terminated

Clinical Performance Evaluation of the C2i-Test

Muscle-Invasive Bladder Carcinoma

United States
University of Michigan Rogel Cancer Center

Terminated

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

Bladder Cancer | Urothelial Cancer

United States
Peking University First Hospital

Unknown

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients

Upper Tract Urothelial Carcinoma | Bladder Recurrence | Nephroureterectomy

China
Peking University First Hospital

Unknown

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients

Upper Tract Urothelial Carcinoma | Bladder Recurrence

China
University of Washington
National Cancer Institute (NCI)

Recruiting

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Bladder Carcinoma | Recurrent Prostate Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Localized... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Stage III Renal Cell Cancer | Recurrent Bladder Carcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer

Urothelial Carcinoma of the Bladder

United States
Guarionex J. Decastro
Sanofi

Active, not recruiting

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (CGC)

Urothelial Carcinoma of the Urinary Bladder

United States
Tianjin Medical University Second Hospital

Recruiting

A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

Bladder Urothelial Carcinoma

China
University of California, Irvine

Recruiting

mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer

Muscle-Invasive Bladder Cancer | Urothelial Bladder Cancer

United States
RenJi Hospital

Recruiting

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Urothelial Carcinoma Bladder | PD-1 Inhibitor

China
Fundacion Oncosur
Apices Soluciones S.L.

Active, not recruiting

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

Invasive Bladder Cancer

Spain
Chinese PLA General Hospital
Beijing GeneX Health Technology Co., Ltd

Recruiting

Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

Muscle-Invasive Bladder Carcinoma

China
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
Sesen Bio, Inc.

Completed

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Urinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors

United States, Canada
Memorial Sloan Kettering Cancer Center
Bayer

Terminated

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer | URINARY BLADDER

United States
Massachusetts General Hospital
Biocompatibles UK Ltd

Recruiting

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Bladder Cancer | Metastatic Urothelial Carcinoma

United States
Fox Chase Cancer Center

Withdrawn

A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) (CARMA)

Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Metastatic Urethral Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Ureter Cancer AJCC v7 | Stage IV Urethral Cancer AJCC v7 | Ureter Urothelial Carcinoma and other conditions

United States, Canada
Fundacio Puigvert
KARL STORZ Endoscopy-America, Inc.

Recruiting

En Bloc Bladder Tumor Resection: Prospective Randomized Study

Bladder Cancer | Urothelial Carcinoma Bladder

Spain
RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Non Muscle Invasive Bladder Cancer

China
AstraZeneca
Parexel

Recruiting

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO)

Non-Muscle- Invasive Bladder Cancer

United States
University of Texas Southwestern Medical Center

Recruiting

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Non-muscle-invasive Bladder Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Non-Muscle Invasive Bladder Cancer (NMIBC)

United States
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Solid Tumor | Bladder Cancer | Non-muscle-invasive Bladder Cancer

United States
Latin American Cooperative Oncology Group

Terminated

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Bladder Cancer | Urothelial Carcinoma

Brazil

Clinical Trials on Invasive Bladder Urothelial Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations